CTOs on the Move

OmniSonics Medical Technologies

www.omnisonics.com

 
At OmniSonics, we are a team of highly dedicated people focused on building technology that will allow physicians to improve the quality of life for patients suffering from vascular diseases - such as deep vein thrombosis (DVT) and peripheral arterial
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Caring People

Caring People offering 24 hour home care service for the elderly and help seniors daily living at home. Hire 24-hour caregivers for your loved one.

Seasons

Seasons Hospice & Palliative Care (SHPC) is a community-based organization with an ongoing mission to find creative solutions that add quality to end-of-life care. The caregivers at SHPC hold steadfast to the patient/family focus of hospice care. We recognize that individuals and families are the experts in their own care, and we continuously strive for excellence beyond accepted standards. We are born into a world of comfort, warmth and love, and it our belief that we should all leave this world in the same way. To further that goal, we work with communities to increase the awareness of hospice as part of the continuum of care.

Hialeah Technology Center

Hialeah Technology Center is a Hialeah, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Greene Health Partners

Greene Health Partners is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Greene Health Partners is based in Xenia, OH. You can find more information on Greene Health Partners at www.greenehealth.org

Elcelyx Therapeutics

lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.